Abstract
Ischemic heart disease is a life-threatening disorder; especially acute coronary syndrome (ACS) is a major cause of death in the world. Coronary arteries of angiographic significant stenosis with patients’ symptoms or certified myocardial ischemia are generally administered by revascularization therapies, such as coronary artery bypass surgery and percutaneous coronary intervention using balloon angioplasty or metallic stent deployment. However, ACS often arises from mild to moderate stenosis without the evidence of myocardial ischemia in a brief period. Accurate prospect of ACS is therefore complicated at the present, and pharmacological intervention as preventive insurance is extremely important. Among medical treatment for coronary risk factors, lipid-lowering therapy represented by administration of HMG-CoA reductase inhibitor (statin) is the most powerful, practical, and established way to prevent against ACS. From an angioscopic point of view, morphological changes in atherosclerotic coronary plaque focused on lipid-lowering intervention are reviewed in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1999;92:657–71.
Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;1004:365–72.
Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354–63.
Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–72.
Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart. 2004;90:1385–91.
Schaar JA, Muller JE, Falk E, et al. Terminology of high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, Santorini, Greece. Eur Heart J. 2004;25:1077–82.
Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation. 1990;82:II30–42.
Stone GW, Maehara A, Lansky AJ, et al. A prospective natural history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.
Honda Y, Fitzgerald PJ. Frontiers in intravascular imaging technologies. Circulation. 2008;117:2024–37.
Nair A, Kuban BD, Tuzcu EM, et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation. 2002;106:2200–6.
Kawasaki M, Takatsu H, Noda T, et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation. 2002;105:2487–92.
Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation. 2002;106:1640–5.
Moreno PR, Lodder RA, Purushothaman KR, et al. Detection of lipid pool, thin cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation. 2002;105:923–7.
Asakura M, Ueda Y, Nanto S, et al. Remodeling of in-stent neointima, which become thinner and transparent over 3 years: serial angiographic and angioscopic follow-up. Circulation. 1998;97:2003–6.
Sakai S, Mizuno K, Yokoyama S, et al. Morphological changes in infarct-related plaque after coronary stent placement: a serial angioscopy study. J Am Coll Cardiol. 2003;42:1558–65.
Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108–11.
Takano M, Ohba T, Inami S, et al. Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J. 2006;27:2189–95.
Awata M, Kotani J, Uematsu M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stent. Circulation. 2007;116:910–16.
Takano M, Yamamoto M, Xie Y, et al. Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart. 2007;93:1353–6.
Takano M, Yamamoto M, Murakami D, et al. Lack of association large angiographic late loss and low risk of in-stent thrombus: angioscopic comparison between paclitaxel- and sirolimus-eluting stent. Circ Cardiovasc Interv. 2008;1:20–7.
Takano M, Mizuno K. Coronary angioscopic evaluation for serial changes of luminal appearance after pharmacological and catheter interventions. Circ J. 2010;74:240–5.
Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326:287–91.
Okamatsu K, Takano M, Sakai S, et al. Elevated troponin T levels and lesion characteristics in non-ST elevation acute coronary syndromes. Circulation. 2004;109:465–70.
MacNeill BD, Lowe HC, Takano M, et al. Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vasc Biol. 2003;23:1333–42.
Mizuno K, Miyamoto A, Satomura K, et al. Angioscopic morphology in patients with acute coronary disorders. Lancet. 1991;337:809–12.
Ueda Y, Asakura M, Yamaguchi O, et al. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol. 2001;38:1916–22.
Takano M, Mizuno K, Yokoyama S, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003;42:680–6.
Ishibashi F, Yokoyama S, Miyahara K, et al. Quantitative colorimetry of atherosclerotic plaque using the L*a*b* color space during angioscopy for the detection of lipid cores underneath thin fibrous cap. Int J Cardiovasc Imaging. 2007;6:679–91.
Kawano T, Honye J, Takayama T, et al. Compositional analysis of angioscopic yellow plaques with intravascular ultrasound radiofrequency data. Int J Cardiol. 2008;125:74–8.
Yamamoto M, Takano M, Okamatsu K, et al. Relationship between thin cap fibroatheroma identified by virtual histology and angioscopic yellow plaque in quantitative analysis with colorimetry. Circ J. 2009;73:497–502.
Kubo T, Imanishi T, Takarada S, et al. Implication of plaque color classification for assessing plaque vulnerability: a coronary angioscopy and optical coherence tomography investigation. JACC Cardiovasc Interv. 2008;1:74–80.
Takano M, Jang IK, Inami S, et al. In vivo comparison of optical coherence tomography and angioscopy for the evaluation of coronary plaque characteristics. Am J Cardiol. 2008;101:471–6.
Takano M, Mizuno K, Okamatsu K, et al. Mechanical and structural characteristics of vulnerable plaques: analysis by coronary angioscopy and intravascular ultrasound. J Am Coll Cardiol. 2001;38:99–104.
Ueda Y, Ohtani T, Shimizu M, et al. Assessment of plaque vulnerability by angioscopic classification of plaque color. Am Heart J. 2004;148:333–5.
Uchida Y, Nakamura F, Tomaru T, et al. Prediction of acute coronary syndromes by percutaneous coronary angioscopy in patients with stable angina. Am Heart J. 1995;130:195–203.
Ohtani T, Ueda Y, Mizote I, et al. Number of yellow plaques detected in a coronary artery is associated with future risk of acute coronary syndrome: detection of vulnerable patients by angioscopy. J Am Coll Cardiol. 2006;247:2194–200.
Ishibashi F, Mizuno K, Kawamura A, et al. High yellow color intensity by angioscopy with quantitative colorimetry to identify high-risk features in culprit lesions of patients with acute coronary syndromes. Am J Cardiol. 2007;100:1207–11.
Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007;50:933–9.
Brown MS, Goldstein JL. Atherosclerosis. Scavenging for receptors. Nature. 1990;343:508–9.
Shah PK, Falk E, Badimon JJ, et al. human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;15:1565–9.
Bocan TM. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Investig Drugs. 2002;3:1312–17.
No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–89.
No authors listed. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.
No authors listed. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet. 1994;344:633–8.
Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol. 2001;37:1284–8.
Takano M, Inami S, Ishibashi F, et al. Angioscopic follow-up study of non-culprit ruptured plaques. J Am Coll Cardiol. 2005;45:652–8.
Hirayama A, Saito S, Ueda Y, et al. Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J. 2009;73:718–25.
Kodama K, Komatsu S, Ueda Y, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound-the TOGETHAR trial. Circ J. 2010;74:1922–8.
Osawa H, Uchida Y, Fujimori Y, et al. Angioscopic evaluation of stabilizing effects of an antilipidemic agent, bezafibrate, on coronary artery plaques in patients with coronary artery disease: a multicenter prospective study. Jpn Heart J. 2002;43:319–31.
Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases activity and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–33.
Takarada S, Imanishi T, Kubo T, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2009;202:491–7.
Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104:387–92.
Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation. 2004;110:1061–8.
Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–65.
Schoenhagen P, Tuzcu EM, Apperson-Hansen C, et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation. 2006;113:2826–34.
Kawasaki M, Sano K, Okubo M, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005;45:1946–53.
Hong MK, Park DW, Lee CW, et al. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv. 2009;2:679–88.
Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62:21–9.
Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–25.
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73.
Yokoyama S, Takano M, Yamamoto M, et al. Extended follow-up by serial angioscopic observation for bare-metal stents in native coronary arteries: from healing response to atherosclerotic transformation of neointima. Circ Cardiovasc Interv. 2009;2:205–12.
Takano M, Yamamoto M, Inami S, et al. Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents: extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol. 2009;55:26–32.
Higo T, Ueda Y, Oyabu J, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus-eluting stent: an angioscopic study. JACC Cardiovasc Imaging. 2009;2:616–24.
Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug eluting stents. J Am Coll Cardiol. 2011;57:1314–22.
Takano M, Yamamoto M, Mizuno K. Two cases of coronary stent thrombosis very late after bare-metal stenting. JACC Cardiovasc Interv. 2009;2:1286–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Japan
About this chapter
Cite this chapter
Takano, M. (2015). Pharmacological Intervention. In: Mizuno, K., Takano, M. (eds) Coronary Angioscopy. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55546-9_19
Download citation
DOI: https://doi.org/10.1007/978-4-431-55546-9_19
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55545-2
Online ISBN: 978-4-431-55546-9
eBook Packages: MedicineMedicine (R0)